<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02372786</url>
  </required_header>
  <id_info>
    <org_study_id>MEC-2014-517_OPTICA</org_study_id>
    <nct_id>NCT02372786</nct_id>
  </id_info>
  <brief_title>7% Lidocaine/7% Tetracaine Cream Versus 2,5% Lidocaine / 2,5% Prilocaine Cream</brief_title>
  <acronym>OPTICA</acronym>
  <official_title>A Double Blind Randomized Controlled Trial Comparing the Efficacy of 7% Lidocaine / 7% Tetracaine Cream Versus 2,5% Lidocaine / 2,5% Prilocaine Cream for Local Anaesthesia During Laser Treatment of Acne Keloidalis Nuchae and Tattoo Removal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of 7% lidocaine / 7% tetracaine cream
      and 2,5% lidocaine / 2,5% prilocaine cream in reducing self-reported pain during a single
      laser procedure in the treatment of acne keloidalis nuchae and tattoo removal.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study we will compare the efficacy of 7% lidocaine / 7% tetracaine cream and 2,5%
      lidocaine / 2,5% prilocaine cream in reducing self-reported pain during a single laser
      procedure in the treatment of acne keloidalis nuchae and tattoo removal. Patients will be
      asked to fill in questionnaires to:

        -  assess the severity of pain experienced (VAS score) during laser treatment,

        -  evaluate whether the pain relief is adequate and,

        -  evaluate the amount of money patients would be willing to pay for the cream that
           provided the 'best' pain relief.

      One week after the visit the patient will have a telephone consultation. The patients will be
      asked if they experienced any symptoms, which will be recorded as adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-reported pain (10 point visual analog scale).</measure>
    <time_frame>5 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adequate pain relief (yes/no);</measure>
    <time_frame>10 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>willing to spend around 25 euro for best pain relief (yes/no).</measure>
    <time_frame>10 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To monitor the nature and frequency of adverse events</measure>
    <time_frame>one week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Tattoo</condition>
  <condition>Acne Keloidalis Nuchae</condition>
  <arm_group>
    <arm_group_label>Acne Keloidalis Nuchae</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2,5% lidocaine / 2,5% prilocaine cream and 7% lidocaine / 7% tetracaine cream will be applied for 60 minutes. After removal of the creams patients will recieve laser hair removal treatment using a neodymium-doped yttrium aluminium garnet (Nd:Yag) laser.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tattoo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2,5% lidocaine / 2,5% prilocaine cream and 7% lidocaine / 7% tetracaine cream will be applied for 60 minutes. After removal of the creams patients will recieve laser tattoo removal treatment using a Q-switched nd Yag laser.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2,5% lidocaine / 2,5% prilocaine cream</intervention_name>
    <description>The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thick layer of 2,5% lidocaine / 2,5% prilocaine cream will be applied on one side to the intact skin under plastic occlusion (average of 1,5-2g per 10 cm2) 60 minutes before laser treatment.</description>
    <arm_group_label>Acne Keloidalis Nuchae</arm_group_label>
    <arm_group_label>Tattoo</arm_group_label>
    <other_name>Emla®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7% lidocaine / 7% tetracaine cream</intervention_name>
    <description>The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thin layer of 7% lidocaine / 7% tetracaine cream (1mm) will be applied on the other side to the intact skin (average of 1,3g Pliaglis per 10 cm2) 60 minutes before laser treatment.</description>
    <arm_group_label>Acne Keloidalis Nuchae</arm_group_label>
    <arm_group_label>Tattoo</arm_group_label>
    <other_name>Pliaglis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser</intervention_name>
    <description>Acne keloidalis nuchae: during this study a 1064 nm Nd:yag laser with a spot size of 7-10 mm, and a fluence of 35-60J/cm2, (depending on the effective and safe clinical response), a pulse duration of 20-35 ms and 2 passes will be used.</description>
    <arm_group_label>Acne Keloidalis Nuchae</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Q-switched nd Yag laser</intervention_name>
    <description>Tattoo removal: we will use a 3 mm spotsize and a fluence depending on the absorption of the laser light, which is visible as skin whitening.</description>
    <arm_group_label>Tattoo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Subject has provided written informed consent;

               -  Subject is ≥ 18 years of age at time of screening;

               -  Group A: subjects with acne keloidalis nuchae;

               -  Group B: subjects with an uniform, black, professionally placed tattoo

        Exclusion Criteria:

          -  • Known sensitivity to any components of the test materials;

               -  Pregnant or breast-feeding women;

               -  Use of any other pain medication during past 24 hours prior to the laser
                  treatment;

               -  Damaged skin at the designated treatment site;

               -  Blister formation and/or scar formation after test-treatment with standard laser
                  settings;

               -  Any medical or psychiatric condition which, in the investigator's opinion, would
                  preclude the participant from adhering to the protocol or completing the study
                  per protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martijn van Doorn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid-Holland</state>
        <zip>3015CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>February 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2015</study_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>M.B.A. van Doorn</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>7% lidocaine / 7% tetracaine cream</keyword>
  <keyword>2,5% lidocaine / 2,5% prilocaine cream</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Keloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Prilocaine</mesh_term>
    <mesh_term>Tetracaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

